Ortho-Novum Related Published Studies
Well-designed clinical trials related to Ortho-Novum (Norethindrone / Mestranol)
Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. [2003.04]
Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. [2000.05]
A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. [1999.11]
Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. [1998.11]
Bioequivalence of two oral contraceptive drugs containing norethindrone and ethinyl estradiol. [1989.11]
Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are "low-dose" pills really lower? [1989.09]
Well-designed clinical trials possibly related to Ortho-Novum (Norethindrone / Mestranol)
The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants. [2009.07]
The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. [2006.09.11]
Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers. [2002.02]
Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. [2001.08]
Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. [2001.06]
A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. [2000.03]
The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. [1998.02]
Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial. [1992.11]
A comparative study of 35 mcg and 50 mcg combined oral contraceptives: results from a multicenter clinical trial. [1991.11]
Effect of long-term triphasic oral contraceptive use on glucose tolerance and insulin secretion. [1991.07]
A comparative clinical trial of Norinyl 1 + 35 versus Norinyl 1 + 50 in Merida, Yucatan, Mexico. [1990.06]
Initial selection of oral contraceptives. [1990.05]
A comparative study of three oral contraceptives in Ibadan: Norinyl 1/35, Lo-Ovral and Noriday 1/50. [1990.03]
Triphasic Randomized Clinical Trial: comparative frequency of intermenstrual bleeding. [1989.11]
Study design for the Triphasic Randomized Clinical Trial. [1989.11]
Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial. [1989.05]
The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use. [1989.01]
A comparative clinical trial of Norinyl 1/35 versus Brevicon in Rio Clara, Brazil. [1988.11]
A comparative study of Norinyl 1/35 versus Brevicon in Panama City, Panama. [1987.12]
A comparative study of Norinyl 1/35 versus Norinyl 1/50 in Belgrade, Yugoslavia. [1987.11]
The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate. [1984.04]
A comparison of Norinyl and Brevicon in three sites in Sri Lanka. [1983.05]
Other research related to Ortho-Novum (Norethindrone / Mestranol)
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects. [2011.09]
Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study. [2010]
Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. [2008]
The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. [2004.05]
Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. [2004]
Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives. [2000.12]
Comparative effects of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic) on lipid profiles. Investigators from the Lunelle Study Group. [2000.01]
Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group. [1999.10]
The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. [1991.03]
Lipid, carbohydrate, and androgen metabolism in women using a triphasic oral contraceptive containing norethindrone for one year. [1986]
A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids. [1978.12]
Other possibly related research studies
The interaction between St John's wort and an oral contraceptive. [2003.12]
Diagnostic and therapeutic options in obscure gastrointestinal blood loss. [2000.10]
Patient acceptability and satisfaction with Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension). [1999.10]
Altered reflex control of cutaneous circulation by female sex steroids is independent of prostaglandins. [1999.05]
Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent. [1999.04]
Medical therapy for chronic gastrointestinal bleeding of obscure origin. [1998.08]
Dirithromycin increases ethinyl estradiol clearance without allowing ovulation. [1995.07]
A comparative evaluation of oral contraceptive use and associated compliance issues in a rural population. [1995.05]
Porphyria cutanea tarda: pregnancy versus estrogen effect. [1994.08]
A cost-benefit analysis of four hormonal contraceptive methods. [1994.07]
Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. [1993.05]
Hepatic sinusoidal ectasia. [1992.08]
Oral contraceptives and panic disorder. [1992.05]
Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. [1991.10]
Clinical significance of the androgenicity of progestins in hormonal therapy in women. [1990.09]
Detection and management of pathological, non-palpable, cystic adnexal masses. [1990.04]
Contraception. [1990.04]
Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. [1989.05]
Plasma reduced and total ascorbic acid in healthy women: effects of smoking and oral contraception. [1989.01]
The current status of oral contraceptive clinical development in Japan. [1989]
Ovarian response to human menopausal gonadotropin following suppression with oral contraceptives. [1988.09]
Intimal hyperplasia and thrombosis of the visceral arteries in a young woman: possible relation with oral contraceptives and smoking. [1988.06]
[Drug therapy of dysmenorrhea] [1988.03]
Clinical usefulness of plasma androstanediol glucuronide measurements in women with idiopathic hirsutism. [1987.10]
Phasic contraceptive pills and functional ovarian cysts. [1987.06]
The triphasics: insights for effective clinical use. [1987.02]
Rationale for a new triphasic oral contraceptive. [1986]
Effect of long-term hormonal contraception on plasma lipids. [1985.06]
Effect of levonorgestrel contraceptive implants, Norplant, on blood coagulation. [1984.11]
Chromosomally competent ovarian failure at adolescence. [1983.12]
"Effort thrombosis" of the subclavian vein associated with oral contraceptives. [1981.11]
Impairment of antipyrine metabolism by low-dose oral contraceptive steroids. [1981.01]
A comparative study of standard-dose and low-dose oral contraceptives in rural Bangladesh. [1980]
Benign liver cell adenoma associated with use of oral contraceptive agents. [1976.03]
Lack of effect of rifalazil on ethinyl estradiol pharmacokinetics in healthy postmenopausal women. [2007.07]
Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. [2008.04]
|